

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Schaar, Dale G.

eRA COMMONS USER NAME (credential, e.g., agency login): schardg

POSITION TITLE: Associate Professor of Medicine

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Cook College, Rutgers University, New Brunswick, NJ	BA	05/1984	Biochemistry
UMDNJ/Rutgers University (joint degree), New Brunswick, NJ	PhD	05/1991	Microbiology
Rutgers/Robert Wood Johnson Medical School, New Brunswick, NJ	MD	05/1997	Medicine

A. PERSONAL STATEMENT

Clinically, I am a member of the Rutgers Cancer Institute of New Jersey (RCINJ) Hematologic Malignancies and Stem Transplantation Tumor Study Group that possesses a strong translational research focus. As a clinical researcher, I have written and served as the principal investigator of both translational laboratory studies and therapeutic trials for patients with hematologic malignancies. My focuses are acute leukemia, myelodysplastic/myeloproliferative disorders and stem cell transplant. I have served as the Principal Investigator or site Principal Investigator for more than 35 trials to date, including 3 investigator-initiated trials that I have written. In addition to my clinical research background, my basic research experience includes two decades of molecular and cell biology work including the study of miRNAs in hematopoietic cell growth and differentiation, gene transfer techniques, and microarray/bioinformatic analysis. In sum, I have demonstrated my ability to oversee a productive research program in acute leukemia and have accumulated the necessary laboratory experience to support ongoing basic scientific projects.

Ongoing research support I would like to highlight:

Title: "The Role of MicroRNAs in Human Hematopoietic Cell Differentiation"

Role: Principal Investigator

NIH-National Center for Advancing Translational Sciences (Grant) 12/2015- ongoing

Title: "Wee1 and HDAC Inhibition in Relapsed/Refractory AML"

Role: Subrecipient Principal Investigator

B. POSITIONS AND HONORS**Positions and Employment**

2022-present Director of Myeloid Malignancies. Rutgers Cancer Institute of New Jersey, Department of Medicine, Rutgers, The State University of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ.

2014-present Head- Acute Myeloid Leukemia and Myeloproliferative/Myelodysplastic Disorders Group, Rutgers Cancer Institute of New Jersey, Department of Medicine, Rutgers, The State University of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ.

2011 – present	Associate Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
2002 – present	Member, The Cancer Institute of New Jersey, New Brunswick, NJ
2002 – 2011	Assistant Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
1999 – 2002	Oncology Fellowship, Department of Medicine, Division of Hematology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
1997 – 1999	Resident, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
1992 – 1997	Adjunct Assistant Professor, Department of Neuroscience and Cell Biology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ
1991 – 1992	Postdoctoral Associate, Department of Neuroscience and Cell Biology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ
1990 – 1991	Postdoctoral Associate, Department of Molecular Biology, Princeton University, Princeton, NJ
1988 – 1990	Predoctoral Fellow, Department of Pathology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ
1987 – 1990	Graduate Assistant, Department of Pathology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ
1985 – 1987	Graduate Assistant, Department of Molecular Genetics and Microbiology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ

Other Experience and Professional Memberships

2000, 2010	Certification, American Board of Internal Medicine
2002-ongoing	Certification, Medical Oncology

Invited, Elected, or Appointed Extramural Service

1992-1993	Reviewer, <i>Developmental Biology</i>
1994	Reviewer, <i>Neuron</i>
1994-1996	Reviewer, <i>Experimental Neurology</i>
2003	Reviewer, <i>Cancer Research</i>
2006	Reviewer, <i>Apoptosis</i>
2003,2008	Reviewer, <i>Clinical Cancer Research</i>
2013	Reviewer, <i>The International Journal of Biochemistry</i>
2021	Reviewer, <i>Clinical Lymphoma, Myeloma and Leukemia</i>

Honors

2018-ongoing	Principal Investigator- MDS Foundation Center of Excellence MDS Foundation
2000-2002	Amgen Oncology Fellowship
1988-1990	Predoctoral Fellowship, New Jersey Commission on Cancer Research

National Service

C. CONTRIBUTION TO SCIENCE

1. I am the Director of Myeloid Malignancies at the Rutgers Cancer Institute of New Jersey and I serve as a Principal Investigator or Site Principal investigator on multiple clinical trials ranging from Phase 1 to Cooperative Group Phase 3 studies for patients with acute leukemia or myelodysplasia.
 - a. Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study. Cooper DL, Manago J, Patel V, **Schaar D**, Tyno A, Lin Y, Strair R. *Leuk Res*. 2022 Sep 5;122:106934. doi: 10.1016/j.leukres.2022.106934. Online ahead of print.PMID: 36084368.
 - b. Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning. David A. Sallman, Rafael Bejar,* , Guillermo Montalban-Bravo, Sandra E. Kurtin , Alan F. List , Guillermo Garcia-Manero , Stephen D. Nimer,

Casey L. O'Connell , **Dale Schaar**, Janice Butchko , Tracey Iraca , Stephanie Searle. *Leukemia Research Reports*, 2022-01-01, Volume 17, Article 100328.

- c. Checkpoint Inhibitor Immunotherapy during Pregnancy for Relapsed/Refractory Hodgkin Lymphoma. Andrew M. Evens, Justin S. Brandt , Cody J. Peer, Tyler Yin, **Dale G. Schaar**, Faheem Farooq, Brett Mozarsky, William D. Figg, Elad Sharon. Accepted *American Journal of Hematology*. 2022
 - d. The Impact of Prior Salvage Treatment with Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single Center Experience. Jiyeon Joy Park, PharmD, BCOP, Jenny Lin, Esther Huang, PharmD, BCPS, BCOP, **Dale Schaar**, MD, PhD. Accepted *Clinical Lymphoma, Myeloma and Leukemia*. 2021.
2. I have extensive experience in designing and overseeing translational studies studying signal transduction, miRNAs and select genes critical for cell growth in the context of normal and malignant hematopoiesis. I have also established the human gene Programmed Cell Death 2 (PDCD2) as a potential biomarker that predicts relapsed leukemia and functions in cancer cell proliferation.
- a. Barboza, N., Minakhina, S., Medina, D.J., Balsara, B., Greenwood, S., Huzzy, L., Rabson, A.B., Steward, R. and Schaar, D.G. PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia. *Cancer Biol Ther*. 2013 Jun 1;14(6):546-55. doi: 10.4161/cbt.24484.
 - b. Ting Y, Medina DJ, Strair RK, and Schaar DG. Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. (2010) *Biochem Biophys Res Commun*. 394(3):606-11.
 - c. Schaar, Dale G., Medina, Daniel J., Moore, Dirk F., Strair, Roger K. and Ting, Yi. (2009) miR-320 targets transferring receptor 1 (CD71) and inhibits cell proliferation. *Exp. Hematology*. 37(2): 245-55.
 - d. Schaar D, Liu H., Sharma S, Ting Y, Martin J, Krier C, Ciardella M, Osman M, Goodell L, Notterman, DA, Strair RK. (2005) 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced dual-specificity phosphatase expression and AML cell survival. *Leukemia Research*, 29 (2005) 1171-1179.
3. I am a member of the Rutgers Cancer Institute of New Jersey Hematologic Malignancies Group and FACT-accredited Blood and Marrow Transplant Program that provides expert opinion, support and treatment for the residents of New Jersey.